Sellers, William R.

Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth

Sellers, W. R., Novitch, B. G., Miyake, S., Heith, A., Otterson, G. A., Kaye, F. J., Lassar, A. B., & Kaelin, W. G. (1998) · Genes & Development

Cancer-related Molecular PathwaysChromatin Remodeling and Cancer

Cited by 343

Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma

Rahal, R., Frick, M., Romero, R., Korn, J. M., Kridel, R., Chun Chan, F., Meissner, B., Bhang, H.-E., Ruddy, D., Kauffmann, A., et al. (2014) · Nature Medicine

Lymphoma Diagnosis and TreatmentNF-κB Signaling Pathways

Cited by 334

Allosteric inhibition of SHP2: identification of a potent, selective, and orally efficacious phosphatase inhibitor

Garcia Fortanet, J., Chen, C. H.-T., Chen, Y.-N. P., Chen, Z., Deng, Z., Firestone, B., Fekkes, P., Fodor, M., Fortin, P. D., Fridrich, C., et al. (2016) · Journal of Medicinal Chemistry

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 298

Ribociclib (LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4/6 inhibitor in various solid tumors

Tripathy, D., Bardia, A., & Sellers, W. R. (2017) · Clinical Cancer Research

Advanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancer

Cited by 247

Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer

LaMarche, M. J., Acker, M., Argintaru, A., Bauer, D., Boisclair, J., Chan, H., Chen, C. H.-T., Chen, Y.-N., Chen, Z., Deng, Z., et al. (2020) · Journal of Medicinal Chemistry

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 231

Metabolomic adaptations and correlates of survival to immune checkpoint blockade

Li, H., Bullock, K., Gurjao, C., Braun, D., Shukla, S. A., Bossé, D., Lalani, A.-K. A., Gopal, S., Jin, C., Horak, C., et al. (2019) · Nature Communications

Cancer Immunotherapy and BiomarkersTryptophan and brain disorders

Cited by 218

PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling

Halilovic, E., She, Q.-B., Ye, Q., Pagliarini, R., Sellers, W. R., Solit, D. B., & Rosen, N. (2010) · Cancer Research

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 168

Advances in the preclinical testing of cancer therapeutic hypotheses

Caponigro, G., & Sellers, W. R. (2011) · Nature Reviews Drug Discovery

Cancer Cells and MetastasisCancer-related Molecular Pathways

Cited by 165

M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth

Cortés-Cros, M., Hemmerlin, C., Ferretti, S., Zhang, J., Gounarides, J. S., Yin, H., Muller, A., Haberkorn, A., Chene, P., Sellers, W. R., et al. (2013) · Proceedings of the National Academy of Sciences

Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and Cancer

Cited by 159

PTEN nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor suppression

Chang, C.-J., Mulholland, D. J., Valamehr, B., Mosessian, S., Sellers, W. R., & Wu, H. (2008) · Molecular and Cellular Biology

PI3K/AKT/mTOR signaling in cancerCancer-related Molecular Pathways

Cited by 155

An Oncogenic Role for ETV1 in Melanoma

Jané-Valbuena, J., Widlund, H. R., Perner, S., Johnson, L. A., Dibner, A. C., Lin, W. M., Baker, A. C., Nazarian, R. M., Vijayendran, K. G., Sellers, W. R., et al. (2010) · Cancer Research

Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management

Cited by 115

Cells Degrade a Novel Inhibitor of Differentiation with E1A-Like Properties upon Exiting the Cell Cycle

Miyake, S., Sellers, W. R., Safran, M., Li, X., Zhao, W., Grossman, S. R., Gan, J., DeCaprio, J. A., Adams, P. D., & Kaelin, W. G. (2000) · Molecular and Cellular Biology

Cancer-related Molecular PathwaysUbiquitin and proteasome pathways

Cited by 112

Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6– Reactivating Rb in cancer.

Kim, S., Loo, A., Chopra, R., Caponigro, G., Huang, A., Vora, S., Parasuraman, S., Howard, S., Keen, N., Sellers, W., et al. (2013) · Molecular Cancer Therapeutics

Advanced Breast Cancer TherapiesCancer-related Molecular Pathways

Cited by 106

Molecular basis for substrate recruitment to the PRMT5 methylosome

Mulvaney, K. M., Blomquist, C., Acharya, N., Li, R., Ranaghan, M. J., O’Keefe, M., Rodriguez, D. J., Young, M. J., Kesar, D., Pal, D., et al. (2021) · Molecular Cell

Cancer-related gene regulationRNA modifications and cancer

Cited by 93

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53–MDM2 Inhibitor HDM201

Jeay, S., Ferretti, S., Holzer, P., Fuchs, J., Chapeau, E. A., Wartmann, M., Sterker, D., Romanet, V., Murakami, M., Kerr, G., et al. (2018) · Cancer Research

Cancer-related Molecular PathwaysCell death mechanisms and regulation

Cited by 87

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

Jeay, S., Gaulis, S., Ferretti, S., Bitter, H., Ito, M., Valat, T., Murakami, M., Ruetz, S., Guthy, D. A., Rynn, C., et al. (2015) · eLife

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 85

Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf −/− mouse model

Chapeau, E. A., Gembarska, A., Durand, E. Y., Mandon, E., Estadieu, C., Romanet, V., Wiesmann, M., Tiedt, R., Lehar, J., de Weck, A., et al. (2017) · Proceedings of the National Academy of Sciences

Cancer-related Molecular PathwaysChromatin Remodeling and Cancer

Cited by 64

Selective Ablation of Retinoblastoma Protein Function by the RET Finger Protein

Krützfeldt, M., Ellis, M., Weekes, D. B., Bull, J. J., Eilers, M., Vivanco, M. D. M., Sellers, W. R., & Mittnacht, S. (2005) · Molecular Cell

Cancer-related Molecular PathwaysGenomics and Chromatin Dynamics

Cited by 48

Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models

Wang, H. Q., Halilovic, E., Li, X., Liang, J., Cao, Y., Rakiec, D. P., Ruddy, D. A., Jeay, S., Wuerthner, J. U., Timple, N., et al. (2017) · eLife

Neuroblastoma Research and TreatmentsLung Cancer Treatments and Mutations

Cited by 45

Are CRISPR Screens Providing the Next Generation of Therapeutic Targets?

Vazquez, F., & Sellers, W. R. (2021) · Cancer Research

CRISPR and Genetic EngineeringChromatin Remodeling and Cancer

Cited by 19